Abcam, ab234435, Anti-KMT2A / MLL antibody [EPR22647-8]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal KMT2A / MLL antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR22647-8,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The KMT2A protein also known as MLL (Mixed-Lineage Leukemia) is a large protein with a molecular weight of approximately 431 kDa. This protein functions as a histone methyltransferase which means it adds methyl groups to histone proteins specifically at the lysine 4 position on histone H3 (H3K4). This modification impacts chromatin structure and gene expression. KMT2A/MLL is chiefly expressed in hematopoietic stem cells and various tissue types indicating its broad role in regulation across the body. The protein features a SET domain a characteristic motif for proteins involved in chromatin modification.
Biological function summary
This methyltransferase plays a significant role in regulating gene expression required for normal hematopoietic development and maintenance. KMT2A/MLL forms part of the multi-protein complex called COMPASS-like complex which is essential for its function in methylation activity. Within this complex it associates with other proteins like WDR5 RBBP5 and ASH2L that collaborate to control transcriptional elongation. KMT2A/MLL is also involved in maintaining the expression of various homeobox (HOX) genes which are critical for embryonic development and cell differentiation.
Pathways
KMT2A/MLL plays an integral role in hematopoietic and developmental signaling pathways. One key pathway is the Wnt signaling pathway important for regulating stem cell pluripotency and cell fate decisions. Another pathway is the Notch signaling pathway important for cell differentiation processes. KMT2A interacts with proteins within these pathways such as CXXC1 which links it to the DNA binding properties required for regulating target gene expression.
KMT2A/MLL is closely linked to leukemia notably acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). A significant factor contributing to these associations is the gene fusions involving KMT2A often created during chromosomal translocations which result in oncogenic activation. In these leukemias it can form fusion proteins like MLL-AF4 impacting the normal regulatory activities of KMT2A. This aberrant interaction with proteins such as MEN1 can contribute to oncogenic processes by altering transcription and leading to uncontrolled cell growth.